435 related articles for article (PubMed ID: 15265488)
1. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
Dutta AK; Venkataraman SK; Fei XS; Kolhatkar R; Zhang S; Reith ME
Bioorg Med Chem; 2004 Aug; 12(16):4361-73. PubMed ID: 15265488
[TBL] [Abstract][Full Text] [Related]
2. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
3. Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.
Brown DA; Mishra M; Zhang S; Biswas S; Parrington I; Antonio T; Reith ME; Dutta AK
Bioorg Med Chem; 2009 Jun; 17(11):3923-33. PubMed ID: 19427222
[TBL] [Abstract][Full Text] [Related]
4. Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.
Gopishetty B; Zhang S; Kharkar PS; Antonio T; Reith M; Dutta AK
Bioorg Med Chem; 2013 Jun; 21(11):3164-74. PubMed ID: 23623679
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
6. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H
J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150
[TBL] [Abstract][Full Text] [Related]
7. Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.
Biswas S; Zhang S; Fernandez F; Ghosh B; Zhen J; Kuzhikandathil E; Reith ME; Dutta AK
J Med Chem; 2008 Jan; 51(1):101-17. PubMed ID: 18072730
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
9. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
van Vliet LA; Rodenhuis N; Dijkstra D; Wikström H; Pugsley TA; Serpa KA; Meltzer LT; Heffner TG; Wise LD; Lajiness ME; Huff RM; Svensson K; Sundell S; Lundmark M
J Med Chem; 2000 Jul; 43(15):2871-82. PubMed ID: 10956195
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
[TBL] [Abstract][Full Text] [Related]
12. Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
Ghosh B; Antonio T; Gopishetty B; Reith M; Dutta A
Bioorg Med Chem; 2010 Aug; 18(15):5661-74. PubMed ID: 20605099
[TBL] [Abstract][Full Text] [Related]
13. Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
Biswas S; Hazeldine S; Ghosh B; Parrington I; Kuzhikandathil E; Reith ME; Dutta AK
J Med Chem; 2008 May; 51(10):3005-19. PubMed ID: 18410082
[TBL] [Abstract][Full Text] [Related]
14. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.
Ghosh B; Antonio T; Reith ME; Dutta AK
J Med Chem; 2010 Mar; 53(5):2114-25. PubMed ID: 20146482
[TBL] [Abstract][Full Text] [Related]
17. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
18. Novel (R)-2-amino-5-fluorotetralins: dopaminergic antagonists and inverse agonists.
Malmberg A; Höök BB; Johansson AM; Hacksell U
J Med Chem; 1996 Oct; 39(22):4421-9. PubMed ID: 8893836
[TBL] [Abstract][Full Text] [Related]
19. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
20. Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats.
Banasikowski TJ; Bespalov A; Drescher K; Behl B; Unger L; Haupt A; Schoemaker H; Sullivan JP; Gross G; Beninger RJ
J Pharmacol Exp Ther; 2010 Nov; 335(2):506-15. PubMed ID: 20724485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
